20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.41% | 15.79% | 27.32% | 27.32% | 60.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.41% | 15.79% | 27.32% | 27.32% | 60.27% |
| Cost of Revenue | 9.33% | -19.00% | 11.37% | 11.37% | 24.20% |
| Gross Profit | -20.00% | 502.07% | 89.95% | 89.95% | 378.01% |
| SG&A Expenses | -5.03% | -49.66% | -25.91% | -25.91% | -6.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.48% | -45.89% | -19.96% | -19.96% | 3.86% |
| Operating Income | 26.62% | 57.67% | 35.97% | 35.97% | 9.82% |
| Income Before Tax | -4.71% | 55.94% | 33.90% | 33.90% | 6.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.71% | 55.94% | 33.90% | 33.90% | 6.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.71% | 55.94% | 33.90% | 33.90% | 6.78% |
| EBIT | 26.62% | 57.67% | 35.97% | 35.97% | 9.82% |
| EBITDA | 26.31% | 58.01% | 35.93% | 35.93% | 9.81% |
| EPS Basic | 2.36% | 56.64% | 34.54% | 34.54% | 7.76% |
| Normalized Basic EPS | 1.06% | 56.67% | 34.55% | 34.55% | 9.00% |
| EPS Diluted | 1.89% | 56.90% | 34.54% | 34.54% | 7.76% |
| Normalized Diluted EPS | 1.06% | 56.67% | 34.55% | 34.55% | 9.00% |
| Average Basic Shares Outstanding | 7.22% | 1.65% | 0.95% | 0.95% | 1.07% |
| Average Diluted Shares Outstanding | 7.22% | 1.65% | 0.95% | 0.95% | 1.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |